Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538275 · ClinicalTrials.gov registry record
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
A clinical trial, sponsored by Medibio Limited.
- Completed
- Registry status
- 80
- Enrollment target
NCT03538275: Completed study, sponsored by Medibio Limited.
NCT03538275 is a clinical trial that has completed, run by Medibio Limited. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538275 has completed, sponsored by Medibio Limited.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize autonomic, circadian, and sleep patterns before and during the initial 8 weeks of pharmacologic therapy for moderate-to-severe depression. The study will also explore any differences in these measures between treatment responders and non-responders, and between depression subtypes, including bipolar and unipolar depression. The study will also characterize longitudinal, ambulatory EEG measures throughout the observation period.
Primary Outcome
The Medibio platform will use 24 hours recording to monitor disease severity
Interventions
- OTHER Monitoring test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-03-13 |
| Est. Completion | 2019-12-31 |
What the finished NCT03538275 record still lists
NCT03538275 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Monitoring test is the first listed.
NCT03538275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03538275 about?
NCT03538275 is a clinical study titled "Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes". An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize...
What is the current status of trial NCT03538275?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2018-03-13. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03538275?
The interventions under investigation include: Monitoring test (OTHER).
Who is sponsoring clinical trial NCT03538275?
This trial is sponsored by Medibio Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI